{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+IV&page=5",
    "query": {
      "intervention": "Diphenhydramine IV",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 155,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+IV&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine+IV&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T19:06:25.502Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00655850",
      "title": "Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Avastin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2008-03",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655850"
    },
    {
      "nct_id": "NCT06043323",
      "title": "A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-01-08",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06043323"
    },
    {
      "nct_id": "NCT02541643",
      "title": "Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elotuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sundar Jagannath",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-09-04",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02541643"
    },
    {
      "nct_id": "NCT06412497",
      "title": "MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia",
        "Acquired Amegakaryocytic Thrombocytopenia",
        "Acquired Pure Red Cell Aplasia",
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Rabbit ATG",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cell Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Post-Transplant G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "0 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-05",
      "completion_date": "2036-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06412497"
    },
    {
      "nct_id": "NCT01234922",
      "title": "Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "lisinopril",
          "type": "DRUG"
        },
        {
          "name": "losartan potassium",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "benazepril hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "ramipril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2018-08-28",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234922"
    },
    {
      "nct_id": "NCT07615270",
      "title": "A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "AL Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Anselamimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2026-09",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07615270"
    },
    {
      "nct_id": "NCT04189588",
      "title": "Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oncology Patients Receiving Chemotherapy"
      ],
      "interventions": [
        {
          "name": "Cetirizine HCl 10 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine 50 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "anti-CD20 such as Rituximab or Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TerSera Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2020-03-25",
      "completion_date": "2020-12-23",
      "has_results": true,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 7,
      "location_summary": "Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more",
      "locations": [
        {
          "city": "Napa",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Round Rock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04189588"
    },
    {
      "nct_id": "NCT01729494",
      "title": "Belatacept Early Steroid Withdrawal Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplantation"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "rabbit antithymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "early cessation of steroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2012-09",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729494"
    },
    {
      "nct_id": "NCT00576758",
      "title": "GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "obinutuzumab (RO5072759)",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2008-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-08-19",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00576758"
    },
    {
      "nct_id": "NCT02858726",
      "title": "Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus"
      ],
      "interventions": [
        {
          "name": "CR845 0.5 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "CR845 1 mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "CR845 1.5mcg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cara Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2016-06",
      "completion_date": "2017-03-14",
      "has_results": true,
      "last_update_posted_date": "2020-07-29",
      "last_synced_at": "2026-10-02T19:06:25.502Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Pine Bluff, Arkansas • Long Beach, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02858726"
    }
  ]
}